DUBLIN, July 29, 2021 /CNW/ -- Medtronic plc
(NYSE:MDT), the global leader in medical technology, today
announced the first gynecological (GYN) procedures with the
Hugo™ robotic-assisted surgery (RAS) system. The
six cases included hysterectomies and myomectomies performed by
Salomón Zebede, M.D., and Juan Carlos López, M.D., last week at
Pacifica Salud Hospital in Panama City, Panama.
Advancing access for women to minimally invasive surgical care is a
great responsibility & privilege. -Megan Rosengarten
"As the cornerstone of our new robotic surgery program, the Hugo
RAS system is playing a critical role in bringing the benefits of
minimally invasive surgery to more patients in our region," said
Dr. Zebede. "It was energizing to perform the very first GYN
procedure with the Hugo system, and encouraging to experience
firsthand the possibility this technology brings to women's
health."
Globally, more than 60% of hysterectomies are performed as open
procedures,1 even though minimally invasive surgery
offers fewer complications, shorter hospital stays, and faster
return to normal activities.2-4
Pacifica Salud is the latest institution to join Medtronic's
Partners in Possibility Program, a group of pioneering
hospitals that will be among the first in the world to use the Hugo
RAS system. Earlier this month, the hospital announced its first
five urological cases with the Hugo RAS system. Pacifica Salud is
also an early adopter of Touch Surgery™ Enterprise, a cloud-based
surgical video capture solution that allows surgeons to seamlessly
record, analyze, and share surgical video.
"We are witnessing the dawn of a new era in robotic surgery,"
said Mr. Rafael Cohen, CEO of
Pacifica Salud. "That is made possible by the Hugo system, our
partnership with Medtronic, and our talented team at Pacifica
Salud."
The Hugo RAS system — Medtronic's solution to historic cost and
utilization barriers that have kept surgical robotics out of reach
for many hospitals — is a modular, multi-quadrant platform designed
for a broad range of soft-tissue procedures. In June, Medtronic
announced the first clinical procedures with the Hugo system took
place in Santiago, Chile. That
marked the beginning of the Hugo RAS system patient registry, which
is collecting clinical data to support regulatory submissions
around the world.
"As an OB/GYN, I'm incredibly passionate about advancing women's
health and wellbeing through less invasive solutions that improve
outcomes and enable a better quality of life," said Carla Peron, M.D., chief medical officer of the
Surgical Robotics business, which is part of Medical Surgical
Portfolio at Medtronic. "The first GYN procedures with the Hugo RAS
system represent an exciting step toward expanding access to more
treatment options, including the benefits of robotic-assisted
surgery, to women everywhere."
Medtronic has a longstanding history of making a positive impact
on women's health through technology. The Hugo RAS system joins a
portfolio of gynecological products designed to enable less
invasive surgical treatment of a range of conditions including
abnormal uterine bleeding, uterine fibroids, and endometrial
cancer.
"I'm proud of the work we're doing at Medtronic with our
healthcare partners around the world to improve women's health,"
said Megan Rosengarten, president of
Surgical Robotics. "Advancing access for women to minimally
invasive surgical care is a great responsibility and privilege,
which makes today's announcement about the Hugo system all the more
meaningful."
The Hugo RAS system is not cleared or approved in the U.S. or
Europe. Regulatory requirements of
individual countries and regions will determine availability and
approval or clearance timelines. Touch Surgery Enterprise is
available in the U.S. and Europe;
it is not intended to direct surgery, or aid in diagnosis or
treatment of a disease or condition.
For more information, visit medtronic.com/hugo.
About Medtronic
Medtronic plc (www.medtronic.com),
headquartered in Dublin, Ireland,
is among the world's largest medical technology, services and
solutions companies – alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 90,000 people worldwide, serving physicians,
hospitals and patients in more than 150 countries. The company is
focused on collaborating with stakeholders around the world to take
healthcare Further, Together.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated results.
- Based on internal estimates and Medtronic report, FY20 market
model: procedural volume data.
- Fitch K, Engel T, Bochner A. Cost differences between open and
minimally invasive surgery. Managed Care. 2015
Sep;24(9):40–8.
- Tiwari MM, Reynoso JF, High R, Tsang AW, Oleynikov D. Safety,
efficacy, and cost effectiveness of common laparoscopic procedures.
Surg Endosc. 2011;25(4):1127-1135.
- Roumm AR, Pizzi L, Goldfarb NI, Cohn H. Minimally invasive:
minimally reimbursed? An examination of six laparoscopic surgical
procedures. Surg Innovation. 2005;12(3):261–287.
Contacts:
|
|
|
|
Gary
Jeanfaivre
|
Ryan
Weispfenning
|
Public
Relations
|
Investor
Relations
|
+1-203-833-2104
|
+1-763-505-4626
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/first-gynecological-procedures-performed-with-medtronic-hugo-robotic-assisted-surgery-system-301343980.html
SOURCE Medtronic plc